APREPITANT- aprepitant capsule APREPITANT- aprepitant Sandoz Inc

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES.

APREPITANT capsules, for oral use Initial U.S. Approval: 2003

Aprepitant is a substance P/neurokinin 1 (NK₁) receptor antagonist. <u>Aprepitant capsules is indicated</u>

- in combination with other antiemetic agents, in patients 12 years of age and older for prevention of:
 - acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin (1.1)
 - nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) (1.1)
 - for prevention of postoperative nausea and vomiting (PONV) in adults (1.2)

Limitations of Use (1.3)

- Aprepitant capsules have not been studied for treatment of established nausea and vomiting.
- Chronic continuous administration of aprepitant capsules are not recommended.

DOSAGE AND ADMINISTRATION
<u>Recommended Dosage for Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) (2.1)</u>

- Aprepitant capsules in adults and pediatric patients 12 years of age and older: is 125 mg on Day 1 and 80 mg on Days 2 and 3.
- Administer aprepitant capsules 1 hour prior to chemotherapy on Days 1, 2, and 3. If no chemotherapy is given on Days 2 and 3, administer aprepitant capsules in morning.
- See Full Prescribing Information for recommended dosages of concomitant dexamethasone and 5-HT3 antagonist for HEC and MEC.

Recommended Dosage for PONV (2.2)

• Adults: 40 mg aprepitant capsules within 3 hours prior to induction of anesthesia.

Preparation and Administration (2.3)

- Aprepitant capsules can be administered with or without food.
- Swallow aprepitant capsules whole.
- For details on preparation see Full Prescribing Information.

DOSAGE FORMS AND STRENGTHS				
			ID SINERGINS	
Aprepitant Ca	psules, USP: 40 mg; 80 mg;	125 mg (3)		
• •			CATIONS	
		contrain Dic/	CATIONS	

- Known hypersensitivity to any component of this drug. (4)
- Concurrent use with pimozide. (4)

------ WARNINGS AND PRECAUTIONS ------

- <u>CYP3A4 Interactions</u>: Aprepitant is a substrate, weak-to-moderate inhibitor and inducer of CYP3A4; See Full Prescribing Information for recommendations regarding contraindications, risk of adverse reactions, and dosage adjustments of aprepitant and concomitant drugs. (4, 5.1, 7.1, 7.2)
- <u>Warfarin (a CYP2C9 substrate)</u>: Risk of decreased INR of prothrombin time; monitor INR in 2-week period, particularly at 7 to 10 days, following initiation of aprepitant. (5.2, 7.1)

• <u>Hormonal Contraceptives</u>: Efficacy of contraceptives may be reduced during administration of and for 28 days following the last dose of aprepitant. Use effective alternative or back-up methods of contraception. (5.3, 7.1<u>,</u>8.3)

- Adults: fatigue, diarrhea, asthenia, dyspepsia, abdominal pain, hiccups, white blood cell count decreased, dehydration, and alanine aminotransferase increased
- Pediatrics: neutropenia, headache, diarrhea, decreased appetite, cough, fatigue, hemoglobin decreased, dizziness and hiccups

<u>PONV</u>

Adults: constipation and hypotension

To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc., at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See Full Prescribing Information for a list of clinically significant drug interactions. (4, 5.1, 5.2, 5.3, 7.1, 7.2) See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 12/2020

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

- 1.1 Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)
- 1.2 Prevention of Postoperative Nausea and Vomiting (PONV)
- 1.3 Limitations of Use

2 DOSAGE AND ADMINISTRATION

- 2.1 Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)
- 2.2 Prevention of Postoperative Nausea and Vomiting (PONV)
- 2.3 Administration Instructions

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Clinically Significant CYP3A4 Drug Interactions
- 5.2 Decrease in INR with Concomitant Warfarin
- 5.3 Risk of Reduced Efficacy of Hormonal Contraceptives

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience

7 DRUG INTERACTIONS

- 7.1 Effect of Aprepitant on the Pharmacokinetics of Other Drugs
- 7.2 Effect of Other Drugs on the Pharmacokinetics of Aprepitant

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.3 Females and Males of Reproductive Potential
- 8.4 Pediatric Use
- 8.5 Geriatric Use

- 8.6 Patients with Renal Impairment
- 8.7 Patients with Hepatic Impairment
- **10 OVERDOSAGE**
- **11 DESCRIPTION**

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

- 14.1 Prevention of Nausea and Vomiting Associated with HEC in Adults
- 14.2 Prevention of Nausea and Vomiting Associated with MEC in Adults

14.3 Prevention of Nausea and Vomiting Associated with HEC or MEC in Pediatric Patients

14.4 Prevention of PONV in Adults

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)

Aprepitant capsules, in combination with other antiemetic agents, are indicated in patients 12 years of age and older for the prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
- nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

1.2 Prevention of Postoperative Nausea and Vomiting (PONV)

Aprepitant capsules are indicated in adults for the prevention of postoperative nausea and vomiting.

1.3 Limitations of Use

- Aprepitant capsules have not been studied for the treatment of established nausea and vomiting.
- Chronic continuous administration of aprepitant capsules is not recommended because it has not been studied, and because the drug interaction profile may change during chronic continuous use.

2 DOSAGE AND ADMINISTRATION

2.1 Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)

Adults and Pediatric Patients 12 Years of Age and Older

The recommended oral dosage of aprepitant capsules, dexamethasone, and a 5-HT₃ antagonist in adults and pediatric patients 12 years of age and older who can swallow oral capsules, for the prevention of nausea and vomiting associated with administration of HEC or MEC is shown in **Table 1** or **Table 2**, respectively.

Table 1: Recommended Dosing for the Prevention of Nausea and VomitingAssociated with HEC

	Population	Day1	Day 2	Day 3	Day 4
Aprepitant capsules [*]	Adults and Pediatric Patients 12 years and Older	125 mg orally	80 mg orally	80 mg orally	none
Dexamethasone	Adults Pediatric Patients 12 years and Older	12 mg orally If a corticoster coadministered corticosteroid <i>Studies (14.3)</i>]	oid, such as d d, administer dose on Days	dexamethaso 50% of the re	ne, is commended
5-HT ₃ antagonist Adults and Pediatric Patients 12 years and Older		See selected 5-HT ₃ antagonist prescribing information for the recommended dosage		none	none

* Administer aprepitant capsules 1 hour prior to chemotherapy treatment on Days 1, 2, and 3. If no chemotherapy is given on Days 2 and 3, administer aprepitant capsules in the morning.

+ Administer dexamethasone 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 through 4. A 50% dosage reduction of dexamethasone is recommended to account for a drug interaction with aprepitant capsules [see ClinicalPharmacology (12.3)].

Table 2: Recommended Dosing for the Prevention of Nausea and VomitingAssociated with MEC

	Population	Day1	Day 2	Day 3
Aprepitant capsules [*]	Adults and Pediatric Patients 12 years and Older	125 mg orally	80 mg orally	80 mg orally
Dexamethasone	Adults	12 mg orally	none	none
	12 years and Older	If a corticosteroid, such as dexamethasone, is coadministered, administer 50% of the recommended corticosteroid dose on Days through 4 [see Clinical Studies (14.3)]. [†])% of the se on Days 1

5-HT ₃ antagonist	Adults and Pediatric	See the selected	none	none
	Patients 12 years	5-HT ₃ antagonist		
	and Older	prescribing		
		information for		
		recommended		
		dosage		

- * Administer aprepitant capsules 1 hour prior to chemotherapy treatment on Days 1, 2 and 3. If no chemotherapy is given on Days 2 and 3, administer aprepitant capsules in the morning.
- + Administer dexamethasone 30 minutes prior to chemotherapy treatment on Day 1. A 50% dosage reduction of dexamethasone is recommended to account for a drug interaction with aprepitant capsules [see Clinical Pharmacology (12.3)].

2.2 Prevention of Postoperative Nausea and Vomiting (PONV)

The recommended oral dosage of aprepitant capsules in adults is 40 mg within 3 hours prior to induction of anesthesia.

2.3 Administration Instructions

Aprepitant capsules can be administered with or without food.

Aprepitant capsules

• Swallow capsules whole.

3 DOSAGE FORMS AND STRENGTHS

Aprepitant Capsules, USP:

- 40 mg: hard gelatin capsules with opaque white cap and opaque white body containing white to off white colored pellets. The cap is imprinted with 'SZ' and the body is imprinted with '525' in black ink.
- 80 mg: hard gelatin capsules with opaque white cap and clear transparent body containing white to off white colored pellets. The cap is imprinted with 'SZ' and the body is imprinted with '528' in black ink.
- 125 mg: hard gelatin capsules with opaque light blue cap and opaque white body containing white to off white colored pellets. The cap is imprinted with 'SZ' and the body is imprinted with '529' in black ink.

4 CONTRAINDICATIONS

Aprepitant is contraindicated in patients:

- who are hypersensitive to any component of the product. Hypersensitivity reactions including anaphylactic reactions have been reported [see Adverse Reactions (6.2)].
- taking pimozide. Inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of this drug which is a CYP3A4 substrate, potentially causing serious or life-threatening reactions, such as QT prolongation, a known adverse reaction of pimozide [see Warnings and Precautions(5.1)].

5 WARNINGS AND PRECAUTIONS

5.1 Clinically Significant CYP3A4 Drug Interactions

Aprepitant is a substrate, a weak-to-moderate (dose-dependent) inhibitor, and an inducer of CYP3A4.

- Use of aprepitant with other drugs that are CYP3A4 substrates, may result in increased plasma concentration of the concomitant drug.
 - Use of pimozide with aprepitant is contraindicated due to the risk of significantly increased plasma concentrations of pimozide, potentially resulting in prolongation of the QT interval, a known adverse reaction of pimozide [see Contraindications (4)].
- Use of aprepitant with strong or moderate CYP3A4 inhibitors (e.g., ketoconazole, diltiazem) may increase plasma concentrations of aprepitant and result in an increased risk of adverse reactions related to aprepitant.
- Use of aprepitant with strong CYP3A4 inducers (e.g., rifampin) may result in a reduction in aprepitant plasma concentrations and decreased efficacy of aprepitant.

See **Table 10** and **Table 11** for a listing of potentially significant drug interactions [see Drug Interactions (7.1, 7.2)].

5.2 Decrease in INR with Concomitant Warfarin

Coadministration of aprepitant with warfarin, a CYP2C9 substrate, may result in a clinically significant decrease in International Normalized Ratio (INR) of prothrombin time *[see Clinical Pharmacology(12.3)]*. Monitor the INR in patients on chronic warfarin therapy in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of aprepitant with each chemotherapy cycle, or following administration of a single 40 mg dose of aprepitant for the prevention of postoperative nausea and vomiting *[see Drug Interactions (7.1)]*.

5.3 Risk of Reduced Efficacy of Hormonal Contraceptives

Upon coadministration with aprepitant, the efficacy of hormonal contraceptives may be reduced during administration of and for 28 days following the last dose of aprepitant *[see Clinical Pharmacology(12.3)]*. Advise patients to use effective alternative or back-up methods of contraception during treatment with aprepitant and for 1 month following the last dose of aprepitant *[see Drug Interactions(7.1), Use in Specific Populations (8.3)]*.

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The overall safety of aprepitant was evaluated in approximately 6,800 individuals.

Adverse Reactions in Adults in the Prevention of Nausea and Vomiting Associated with HEC and MEC

In 2 active-controlled, double-blind clinical trials in patients receiving highly emetogenic chemotherapy (HEC) (Studies 1 and 2), aprepitant in combination with ondansetron and dexamethasone (aprepitant regimen) was compared to ondansetron and dexamethasone alone (standard therapy) [see Clinical Studies (14.1)].

In 2 active-controlled clinical trials in patients receiving moderately emetogenic chemotherapy (MEC) (Studies 3 and 4), aprepitant in combination with ondansetron and dexamethasone (aprepitant regimen) was compared to ondansetron and dexamethasone alone (standard therapy) [see Clinical Studies (14.2)]. The most common adverse reaction reported in patients who received MEC in pooled Studies 3 and 4 was dyspepsia (6% versus 4%).

Across these 4 studies there were 1412 patients treated with the aprepitant regimen during Cycle 1 of chemotherapy and 1099 of these patients continued into the Multiple-Cycle extension for up to 6 cycles of chemotherapy. The most common adverse reactions reported in patients who received HEC and MEC in pooled Studies 1, 2, 3 and 4 are listed in **Table 5**.

	Aprepitant, ondansetron and dexamethasone [†] (N=1412)	Ondansetron and dexamethasone [‡] (N=1396)
fatigue	13%	12%
diarrhea	9%	8%
asthenia	7%	6%
dyspepsia	7%	5%
abdominal pain	6%	5%
hiccups	5%	3%
white blood cell count decreased	4%	3%
dehydration	3%	2%
alanine aminotransferase increased	3%	2%

Table 5: Most Common Adverse Reactions in Patients Receiving HEC and MEC from a Pooled Analysis of HEC and MEC Studies^{*}

* Reported in ≥3% of patients treated with the aprepitant regimen and at a greater incidence than standard therapy.

† Aprepitant regimen

‡ Standard therapy

In a pooled analysis of the HEC and MEC studies, less common adverse reactions reported in patients treated with the aprepitant regimen are listed in **Table 6**.

Table 6: Less Common Adverse Reactions in Aprepitant-Treated Patients from a Pooled Analysis of HEC and MEC Studies^{*}

Infection and Infestations	oral candidiasis, pharyngitis	
Blood and the Lymphatic System Disorders	anemia, febrile neutropenia, neutropenia, thrombocytopenia	
Metabolism and Nutrition Disorders	decreased appetite, hypokalemia	
Psychiatric Disorders	anxiety	
Nervous System Disorders	dizziness, dysgeusia, peripheral neuropathy	
Cardiac Disorders	palpitations	
Vascular Disorders	flushing, hot flush	
Respiratory, Thoracic and Mediastinal Disorders	cough, dyspnea, oropharyngeal pain	
Gastrointestinal Disorders	s dry mouth, eructation, flatulence, gastritis, gastroesophageal reflux disease, nausea, vomiting	
Skin and Subcutaneous Tissue Disorders	alopecia, hyperhidrosis, rash	
Musculoskeletal and Connective Tissue Disorders	musculoskeletal pain	
General Disorders and Administration Site Condition	edema peripheral, malaise	
Investigations	aspartate aminotransferase increased, blood alkaline phosphatase increased, blood sodium decreased, blood urea increased, proteinuria, weight decreased	

* Reported in >0.5% of patients treated with the aprepitant regimen, at a greater incidence than standard therapy and not previously described in **Table 5**.

In an additional active-controlled clinical study in 1169 patients receiving aprepitant and HEC, the adverse reactions were generally similar to that seen in the other HEC studies with aprepitant.

In another CINV study, Stevens-Johnson syndrome was reported as a serious adverse reaction in a patient receiving the aprepitant regimen with cancer chemotherapy.

Adverse reactions in the Multiple-Cycle extensions of HEC and MEC studies for up to 6 cycles of chemotherapy were generally similar to that observed in Cycle 1.

Adverse Reactions in Pediatric Patients 6 Months to 17 Years of Age in the Prevention of Nausea and Vomiting Associated with HEC or MEC

In a pooled analysis of 2 active-controlled, clinical trials in pediatric patients aged 6 months to 17 years who received highly or moderately emetogenic cancer chemotherapy (Study 5 and a safety study, Study 6), aprepitant in combination with ondansetron with or without dexamethasone (aprepitant regimen) was compared to ondansetron with or without dexamethasone (control regimen).

There were 184 patients treated with the aprepitant regimen during Cycle 1 and 215 patients received open-label aprepitant for up to 9 additional cycles of chemotherapy.

In Cycle 1, the most common adverse reactions reported in pediatric patients treated with the aprepitant regimen in pooled Studies 5 and 6 are listed in **Table 7**.

Table 7: Most Common Adverse Reactions in Aprepitant-Treated PediatricPatients in HEC and MEC Pooled Studies 5 and 6*

	Aprepitant and Ondansetron [†]	Ondansetron [‡] (N=168)
	(N=184)	
neutropenia	13%	11%
headache	9%	5%
diarrhea	6%	5%
decreased appetite	5%	4%
cough	5%	3%
fatigue	5%	2%
hemoglobin decreased	5%	4%
dizziness	5%	1%
hiccups	4%	1%

* Reported in \geq 3% of patients treated with the aprepitant regimen and at a greater incidence than control regimen.

- + Aprepitant regimen
- ‡ Control regimen

Forty-nine patients were treated with ifosfamide chemotherapy in each arm. Two of the patients treated with ifosfamide in the aprepitant arm developed behavioral changes (agitation=1; abnormal behavior=1), whereas no patient treated with ifosfamide in the control arm developed behavioral changes. Aprepitant has the potential for increasing ifosfamide-mediated neurotoxicity through induction of CYP3A4 [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].

Adverse Reactions in Adult Patients in the Prevention of PONV

In 2 active-controlled, double-blind clinical studies in patients receiving general anesthesia (Studies 7 and 8), 40 mg oral aprepitant was compared to 4 mg intravenous ondansetron [*see Clinical Studies (14.4)*].

There were 564 patients treated with aprepitant and 538 patients treated with ondansetron.

The most common adverse reactions reported in patients treated with aprepitant for PONV in pooled Studies 7 and 8 are listed in **Table 8**.

Table 8: Most Common Adverse Reactions in Aprepitant-Treated Patients in a
Pooled Analysis of PONV Studies [*]

	Aprepitant 40 mg (N = 564)	Ondansetron (N = 538)
constipation	9%	8%
hypotension	6%	5%

* Reported in ≥3% of patients treated with the Aprepitant 40 mg and at a greater incidence than ondansetron.

In a pooled analysis of PONV studies, less common adverse reactions reported in patients treated with aprepitant are listed in **Table 9**.

Table 9: Less Common Adverse Reactions in Aprepitant-Treated Patients in aPooled Analysis of PONV Studies*

Infections and Infestations	postoperative infection
Metabolism and Nutrition Disorders	hypokalemia, hypovolemia
Nervous System Disorders	dizziness, hypoesthesia, syncope
Cardiac Disorders	bradycardia
Vascular Disorders	hematoma
Respiratory, Thoracic and Mediastinal Disorders	dyspnea, hypoxia, respiratory depression
Gastrointestinal Disorders	abdominal pain, dry mouth, dyspepsia
Skin and Subcutaneous Tissue Disorders	urticaria
General Disorders and	hypothermia

Administration Site Conditions	
Investigations	blood albumin decreased, bilirubin increased, blood glucose increased, blood potassium decreased
Injury, Poisoning and Procedural Complications	operative hemorrhage, wound dehiscence

* Reported in >0.5% of patients treated with aprepitant and at a greater incidence than ondansetron.

1. Reported in >0.5% of patients treated with aprepitant and at a greater incidence than ondansetron.

In addition, two serious adverse reactions were reported in PONV clinical studies in patients taking a higher than recommended dose of aprepitant: one case of constipation, and one case of sub-ileus.

Other Studies

Angioedema and urticaria were reported as serious adverse reactions in a patient receiving aprepitant in a non-CINV/non-PONV study. (Aprepitant is only approved in the CINV and PONV populations).

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of aprepitant. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Skin and subcutaneous tissue disorders: pruritus, rash, urticaria, Stevens-Johnson syndrome/toxic epidermal necrolysis.

Immune system disorders: hypersensitivity reactions including anaphylactic reactions *[see Contraindications (4)]*.

*Nervous system disorders: i*fosfamide-induced neurotoxicity reported after aprepitant and ifosfamide coadministration.

7 DRUG INTERACTIONS

7.1 Effect of Aprepitant on the Pharmacokinetics of Other Drugs

Aprepitant is a substrate, a weak-to-moderate (dose-dependent) inhibitor, and an inducer of CYP3A4. Aprepitant is also an inducer of CYP2C9 [see Clinical Pharmacology(12.3)].

Aprepitant acts as a moderate inhibitor of CYP3A4 when administered as a 3-day

regimen (125 mg/80 mg/80 mg) and can increase plasma concentrations of concomitant drugs that are substrates for CYP3A4. Aprepitant acts as a weak inhibitor when administered as a single 40 mg dose and has not been shown to alter the plasma concentrations of concomitant drugs that are primarily metabolized through CYP3A4. Some substrates of CYP3A4 are contraindicated with aprepitant [see Contraindications (4)]. Dosage adjustment of some CYP3A4 and CYP2C9 substrates may be warranted, as shown in **Table 10**.

Table 10: Effects of Aprepitant on the Pharmacokinetics of Other Drugs

CYP3A4 Subst	rates
Pimozide	
Clinical Impact	Increased pimozide exposure.
Intervention	Aprepitant is contraindicated [see Contraindications(4)].
Benzodiazepino	95
Clinical Impact	Increased exposure to midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) may increase the risk of adverse reactions <i>[see Clinical Pharmacology(12.3)</i>
Intervention	 <u>3-day aprepitant regimen</u> Monitor for benzodiazepine-related adverse reactions. Depending on the clinical situation (e.g., elderly patients) and degree of monitoring available, reduce the dose of intravenou midazolam <u>Single 40 mg dose of aprepitant</u> No dosage adjustment of the benzodiazepine needed
Dexamethasor	e
Clinical Impact	Increased dexamethasone exposure [see Clinical Pharmacology(12.3)].
Intervention	<u>3-day aprepitant regimen</u> • Reduce the dose of oral dexamethasone by approximately 50% [<i>see Dosage and Administration (2.1)</i>]. <u>Single 40 mg dose of aprepitant</u> • No dosage adjustment of oral dexamethasone needed

Clinical Impact	Increased methylprednisolone exposure [<i>see Clinical Pharmacology(12.3)</i>].
Intervention	 <u>3-day aprepitant regimen</u> Reduce the dose of intravenous methylprednisolone by approximately 25% Reduce the dose of oral methylprednisolone by approximations 50% <u>Single 40 mg dose of aprepitant</u> No dosage adjustment of methylprednisolone needed
Chemotherape	utic agents that are metabolized by CYP3A4
Clinical Impact	Increased exposure of the chemotherapeutic agent may increase the risk of adverse reactions [see Clinical Pharmacology(12.3)].
Intervention	<u>Vinblastine, vincristine, or ifosfamide or other chemotheraperagents</u> • Monitor for chemotherapeutic-related adverse reactions. <u>Etoposide, vinorelbine, paclitaxel, and docetaxel</u> • No dosage adjustment needed.
Hormonal Cont	raceptives
Clinical Impact	Decreased hormonal exposure during administration of and to 28 days after administration of the last dose of aprepitant [see Warnings and Precautions (5.3), Use in Specific Populations (8.3), Clinical Pharmacology (12.3)].
Intervention	Effective alternative or back-up methods of contraception (su as condoms and spermicides) should be used during treatme with aprepitant and for 1 month following the last dose of aprepitant.
Examples	birth control pills, skin patches, implants, and certain IUDs
CYP2C9 Substi	ratoc

Clinical Impact	Decreased warfarin exposure and decreased prothrombin time (INR) [see Warnings and Precautions (5.2), Clinical Pharmacology(12.3)].
Intervention	In patients on chronic warfarin therapy, monitor the prothrombin time (INR) in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day aprepitant regimen with each chemotherapy cycle, or following administration of a single 40 mg dose of aprepitant.
Other	
5-HT3 Antago	onists
Clinical Impact	No change in the exposure of the 5-HT3 antagonist [see Clinical Pharmacology (12.3)].
Intervention	No dosage adjustment needed
Examples	ondansetron, granisetron, dolasetron

7.2 Effect of Other Drugs on the Pharmacokinetics of Aprepitant

Aprepitant is a CYP3A4 substrate [see Clinical Pharmacology (12.3)]. Coadministration of aprepitant with drugs that are inhibitors or inducers of CYP3A4 may result in increased or decreased plasma concentrations of aprepitant, respectively, as shown in **Table 11**.

Table 11: Effects of Other Drugs on Pharmacokinetics of Aprepitant

Moderate to	Moderate to Strong CYP3A4 Inhibitors				
Clinical Impact	Significantly increased exposure of aprepitant may increase the risk of adverse reactions associated with aprepitant [see Adverse Reactions (6.1), Clinical Pharmacology (12.3)].				
Intervention	Avoid concomitant use of aprepitant				
Examples	<u>Moderate inhibitor:</u> diltiazem <u>Strong inhibitors:</u> ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir				

Strong CYP	3A4 Inducers
Clinical Impact	Substantially decreased exposure of aprepitant in patients chronically taking a strong CYP3A4 inducer may decrease the efficacy of aprepitant [see Clinical Pharmacology (12.3)].
Intervention	Avoid concomitant use of aprepitant
Examples	rifampin, carbamazepine, phenytoin

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There are insufficient data on use of aprepitant in pregnant women to inform a drug associated risk. In animal reproduction studies, no adverse developmental effects were observed in rats or rabbits exposed during the period of organogenesis to systemic drug levels (AUC) approximately 1.5 times the adult human exposure at the 125 mg/80 mg/80 mg aprepitant regimen (*see Data*).

The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data

Animal Data

In embryofetal development studies in rats and rabbits, aprepitant was administered during the period of organogenesis at oral doses up to 1000 mg/kg twice daily in rats and up to the maximum tolerated dose of 25 mg/kg/day in rabbits. No embryofetal lethality or malformations were observed at any dose level in either species. The exposures (AUC) in pregnant rats at 1000 mg/kg twice daily and in pregnant rabbits at 125 mg/kg/day were approximately 1.5 times the adult exposure at the 125 mg/80 mg/80 mg aprepitant regimen. Aprepitant crosses the placenta in rats and rabbits.

8.2 Lactation

Risk Summary

Lactation studies have not been conducted to assess the presence of aprepitant in human milk, the effects on the breastfed infant, or the effects on milk production. Aprepitant is present in rat milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for aprepitant and any potential adverse effects on the breastfed infant from aprepitant or from the underlying maternal condition.

8.3 Females and Males of Reproductive Potential

Contraception

Upon administration of aprepitant, the efficacy of hormonal contraceptives may be reduced. Advise females of reproductive potential using hormonal contraceptives to use an effective alternative or back-up non-hormonal contraceptive (such as condoms and spermicides) during treatment with aprepitant and for 1 month following the last dose [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].

8.4 Pediatric Use

Prevention of Nausea and Vomiting Associated with HEC or MEC

The safety and effectiveness of aprepitant capsules in pediatric patients 12 years of age and older for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of HEC, including high-dose cisplatin, and MEC. Use of aprepitant in these age groups is supported by evidence from 302 pediatric patients in a randomized, double-blind, active comparator controlled clinical study (n=207 patients aged 6 months to less than 12 years, n=95 patients aged 12 through 17 years). Aprepitant was studied in combination with ondansetron with or without dexamethasone (at the discretion of the physician) [see Clinical Studies (14.3)]. Adverse reactions were similar to those reported in adult patients [see Adverse Reactions (6.1)].

The safety and effectiveness of aprepitant for the prevention of nausea and vomiting associated with HEC or MEC have not been established in patients less than 6 months.

Prevention of Postoperative Nausea and Vomiting (PONV)

The safety and effectiveness of aprepitant has not been established for the prevention of postoperative nausea and vomiting in pediatric patients.

Juvenile Animal Study

A study was conducted in young rats to evaluate the effects of aprepitant on growth and on neurobehavioral and sexual development. Rats were treated at oral doses up to the maximum feasible dose of 1000 mg/kg twice daily (providing exposure in male rats lower than the exposure at the recommended pediatric human dose and exposure in female rats equivalent to the pediatric human exposure) from the early postnatal period (Postnatal Day 10) through Postnatal Day 58. Slight changes in the onset of sexual maturation were observed in female and male rats; however, there were no effects on mating, fertility, embryonic-fetal survival, or histomorphology of the reproductive organs. There were no effects in neurobehavioral tests of sensory function, motor function, and learning and memory.

8.5 Geriatric Use

Of the 544 adult cancer patients treated with aprepitant in CINV clinical studies, 31% were aged 65 and over, while 5% were aged 75 and over. Of the 1120 adult cancer patients treated with aprepitant in PONV clinical studies, 7% were aged 65 and over, while 2% were aged 75 and over. Other reported clinical experience with aprepitant has not identified differences in responses between elderly and younger patients. In general, use caution when dosing elderly patients as they have a greater frequency of decreased

hepatic, renal or cardiac function and concomitant disease or other drug therapy [see Clinical Pharmacology (12.3)].

8.6 Patients with Renal Impairment

The pharmacokinetics of aprepitant in patients with severe renal impairment and those with end stage renal disease (ESRD) requiring hemodialysis were similar to those of healthy subjects with normal renal function. No dosage adjustment is necessary for patients with any degree of renal impairment or for patients with ESRD undergoing hemodialysis.

8.7 Patients with Hepatic Impairment

The pharmacokinetics of aprepitant in patients with mild and moderate hepatic impairment were similar to those of healthy subjects with normal hepatic function. No dosage adjustment is necessary for patients with mild to moderate hepatic impairment (Child-Pugh score 5 to 9). There are no clinical or pharmacokinetic data in patients with severe hepatic impairment (Child-Pugh score greater than 9). Therefore, additional monitoring for adverse reactions in these patients may be warranted when aprepitant is administered [see Clinical Pharmacology (12.3)].

10 OVERDOSAGE

No specific information is available on the treatment of overdosage.

Drowsiness and headache were reported in one patient who ingested 1440 mg of aprepitant (approximately 11 times the maximum recommended single dose).


In the event of overdose, aprepitant should be discontinued and general supportive treatment and monitoring should be provided. Because of the antiemetic activity of aprepitant, drug-induced emesis may not be effective in cases of aprepitant overdosage.

Aprepitant is not removed by hemodialysis.

11 DESCRIPTION

Aprepitant capsules, USP contain the active ingredient, aprepitant. Aprepitant is a substance P/neurokinin 1 (NK₁) receptor antagonist, an antiemetic agent, chemically described as 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one.

Its empirical formula is $C_{23}H_{21}F_7N_4O_3$, and its structural formula is:



Aprepitant is a white to off-white crystalline solid, with a molecular weight of 534.43. It is practically insoluble in water. Aprepitant is sparingly soluble in ethanol and isopropyl acetate and slightly soluble in acetonitrile.

Each aprepitant capsule, USP for oral administration contains either 40 mg, 80 mg or 125 mg of aprepitant and the following inactive ingredients: hydroxypropyl cellulose, microcrystalline cellulose, sodium lauryl sulfate and sucrose.

The aprepitant capsule shell for 40 mg and 80 mg consists of gelatin and titanium dioxide.

The aprepitant capsule shell for 125 mg consists of FD&C Blue #1, gelatin and titanium dioxide.

The capsule is printed with edible black pharmaceutical ink. The printing ink contains black iron oxide, propylene glycol and shellac.

This product meets USP dissolution test 2.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK₁) receptors. Aprepitant has little or no affinity for serotonin (5-HT₃), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV).

Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with aprepitant have shown that it crosses the blood brain barrier and occupies brain NK₁ receptors. Animal and human studies show that aprepitant augments the antiemetic activity of the 5-HT₃-receptor antagonist ondansetron and the corticosteroid dexamethasone and inhibits both the acute and delayed phases of cisplatin-induced emesis.

12.2 Pharmacodynamics

NK₁ Receptor Occupancy

In two single-blind, multiple-dose, randomized, and placebo-controlled studies, healthy young men received oral aprepitant doses of 10 mg (N=2), 30 mg (N=3), 100 mg (N=3)

or 300 mg (N=5) once daily (0.08, 0.24, 0.8, and 2.4 times the maximum recommended single dose, respectively) for 14 days with 2 or 3 subjects on placebo. Both plasma aprepitant concentration and NK₁ receptor occupancy in the corpus striatum by positron emission tomography were evaluated, at predose and 24 hours after the last dose. At aprepitant plasma concentrations of approximately 10 ng/mL and 100 ng/mL, the NK₁ receptor occupancies were approximately 50% and 90%, respectively. The oral aprepitant regimen for CINV produced mean trough plasma aprepitant concentrations greater than 500 ng/mL in adults, which would be expected to, based on the fitted curve with the Hill equation, result in greater than 95% brain NK₁ receptor occupancy. However, the receptor occupancy for either CINV or PONV dosing regimen has not been determined. In addition, the relationship between NK₁ receptor occupancy and the clinical efficacy of aprepitant has not been established.

Cardiac Electrophysiology

In a randomized, double-blind, positive-controlled, thorough QTc study, a single 200 mg dose of fosaprepitant had no effect on the QTc interval. Maximum aprepitant concentrations after a single 200 mg dose of fosaprepitant were 4- and 9-fold higher than that achieved with oral aprepitant 125 mg and 40 mg, respectively. QT prolongation with the recommended oral aprepitant dosing regimens for CINV and PONV is not expected.

12.3 Pharmacokinetics

Absorption

Following oral administration of a single 40 mg dose of aprepitant in the fasted state, mean area under the plasma concentration-time curve (AUC_{0-∞}) was 7.8 mcg•hr/mL and mean peak plasma concentration (C_{max}) was 0.7 mcg/mL, occurring at approximately 3 hours postdose (T_{max}). The absolute bioavailability at the 40 mg dose has not been determined.

Following oral administration of a single 125 mg dose of aprepitant on Day 1 and 80 mg once daily on Days 2 and 3, the AUC_{0-24hr} was approximately 19.6 mcg•hr/mL and 21.2 mcg•hr/mL on Day 1 and Day 3, respectively. The C_{max} of 1.6 mcg/mL and 1.4 mcg/mL were reached in approximately 4 hours (T_{max}) on Day 1 and Day 3, respectively. At the dose range of 80 to 125 mg, the mean absolute oral bioavailability of aprepitant is approximately 60 to 65%. Oral administration of the capsule with a standard high-fat breakfast had no clinically meaningful effect on the bioavailability of aprepitant.

The pharmacokinetics of aprepitant were non-linear across the clinical dose range. In healthy young adults, the increase in $AUC_{0-\infty}$ was 26% greater than dose proportional between 80 mg and 125 mg single doses administered in the fed state.

Distribution

Aprepitant is greater than 95% bound to plasma proteins. The mean apparent volume of distribution at steady state (Vd_{ss}) was approximately 70 L in humans.

Aprepitant crosses the blood brain barrier in humans [see Clinical Pharmacology (12.1)].

Elimination

Metabolism

Aprepitant undergoes extensive metabolism. *In vitro* studies using human liver

microsomes indicate that aprepitant is metabolized primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19. Metabolism is largely via oxidation at the morpholine ring and its side chains. No metabolism by CYP2D6, CYP2C9, or CYP2E1 was detected. In healthy young adults, aprepitant accounts for approximately 24% of the radioactivity in plasma over 72 hours following a single oral 300-mg dose of [¹⁴C]aprepitant (2.4 times the maximum aprepitant recommended dose), indicating a substantial presence of metabolites in the plasma. Seven metabolites of aprepitant, which are only weakly active, have been identified in human plasma.

Excretion

Following administration of a single intravenous 100 mg dose of [¹⁴C]-aprepitant prodrug to healthy subjects, 57% of the radioactivity was recovered in urine and 45% in feces. A study was not conducted with radiolabeled capsule formulation. The results after oral administration may differ.

Aprepitant is eliminated primarily by metabolism; aprepitant is not renally excreted. The apparent plasma clearance of aprepitant ranged from approximately 62 to 90 mL/min. The apparent terminal half-life ranged from approximately 9 to 13 hours.

Specific Populations

Geriatric Patients

Following oral administration of a single 125 mg dose of aprepitant on Day 1 and 80 mg once daily on Days 2 through 5 (2 additional days of dosing compared to the recommended duration), the AUC_{0-24hr} of aprepitant was 21% higher on Day 1 and 36% higher on Day 5 in elderly (65 years and older) relative to younger adults. The C_{max} was 10% higher on Day 1 and 24% higher on Day 5 in elderly relative to younger adults. These differences are not considered clinically meaningful *[see Use in Specific Populations (8.5)].*

Pediatric Patients

As part of a 3-day regimen, dosing of aprepitant capsules (125 mg/80 mg/80 mg) in 18 pediatric patients (aged 12 through 17 years) achieved a mean AUC_{0-24hr} of 17 mcg•hr/mL on Day 1 with mean peak plasma concentration (C_{max}) at 1.3 mcg/mL occurring at approximately 4 hours. The mean concentrations at the end of Day 2 (N=8) and Day 3 (N=16) were both at 0.6 mcg/mL.

A population pharmacokinetic analysis of aprepitant in pediatric patients (aged 6 months through 17 years) suggests that sex and race have no clinically meaningful effect on the pharmacokinetics of aprepitant.

Male and Female Patients

Following oral administration of a single dose of aprepitant ranging from 40 mg to 375 mg (3 times the maximum aprepitant recommended dose), the AUC_{0-24hr} and C_{max} are 9% and 17% higher in females as compared with males. The half-life of aprepitant is approximately 25% lower in females as compared with males and T_{max} occurs at approximately the same time. These differences are not considered clinically meaningful.

Racial or Ethnic Groups

Following oral administration of a single dose of aprepitant ranging from 40 mg to 375 mg (3 times the maximum aprepitant recommended dose), the AUC_{0-24hr} and C_{max} are

approximately 27% and 19% higher in Hispanics as compared with Caucasians. The AUC_{0-24hr} and C_{max} were 74% and 47% higher in Asians as compared to Caucasians. There was no difference in AUC_{0-24hr} or C_{max} between Caucasians and Blacks. These differences are not considered clinically meaningful.

Patients with Renal Impairment

A single 240 mg dose of aprepitant (approximately 1.9 times the maximum aprepitant recommended dose) was administered to patients with severe renal impairment (creatinine clearance less than 30 mL/min/1.73 m² as measured by 24-hour urinary creatinine clearance) and to patients with end stage renal disease (ESRD) requiring hemodialysis.

In patients with severe renal impairment, the AUC_{0-∞} of total aprepitant (unbound and protein bound) decreased by 21% and C_{max} decreased by 32%, relative to healthy subjects (creatinine clearance greater than 80 mL/min estimated by Cockcroft-Gault method). In patients with ESRD undergoing hemodialysis, the AUC_{0-∞} of total aprepitant decreased by 42% and C_{max} decreased by 32%. Due to modest decreases in protein binding of aprepitant in patients with renal disease, the AUC of pharmacologically active unbound drug was not significantly affected in patients with renal impairment compared with healthy subjects. Hemodialysis conducted 4 or 48 hours after dosing had no significant effect on the pharmacokinetics of aprepitant; less than 0.2% of the dose was recovered in the dialysate [see Use in Specific Populations (8.6)].

Patients with Hepatic Impairment

Following administration of a single 125 mg dose of aprepitant on Day 1 and 80 mg once daily on Days 2 and 3 to patients with mild hepatic impairment (Child-Pugh score 5 to 6), the AUC_{0-24hr} of aprepitant was 11 % lower on Day 1 and 36% lower on Day 3, as compared with healthy subjects given the same regimen. In patients with moderate hepatic impairment (Child-Pugh score 7 to 9), the AUC_{0-24hr} of aprepitant was 10% higher on Day 1 and 18% higher on Day 3, as compared with healthy subjects given the same regimen. These differences in AUC_{0-24hr} are not considered clinically meaningful. There are no clinical or pharmacokinetic data in patients with severe hepatic impairment (Child-Pugh score greater than 9) [see Use in Specific Populations(8.7)].

Body Mass Index (BMI)

For every 5 kg/m² increase in BMI, AUC_{0-24hr} and C_{max} of aprepitant decrease by 9% and 10%. BMI of subjects in the analysis ranged from 18 kg/m² to 36 kg/m². This change is not considered clinically meaningful.

Drug Interactions Studies

Aprepitant is a substrate, a weak-to-moderate (dose-dependent) inhibitor, and an inducer of CYP3A4. Aprepitant is also an inducer of CYP2C9. Aprepitant is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter.

Effects of Aprepitant on the Pharmacokinetics of Other Drugs

CYP3A4 substrates (i.e., midazolam): Interactions between aprepitant and coadministered midazolam are listed in **Table 12** (increase is indicated as " \uparrow ", decrease as " \downarrow ", no change as " \leftrightarrow ").

Table 12: Pharmacokinetic Interaction Data for Aprepitant andCoadministered Midazolam

Dosage of Aprepitant	Dosage of Midazolam	Observed Drug Interactions
aprepitant 125 mg on Day 1 and 80 mg on Days 2 to 5	oral 2 mg single dose on Days 1 and 5	midazolam AUC ↑ 2.3-fold on Day 1 and ↑ 3.3-fold on Day 5 <i>[see Drug</i> <i>Interactions (7.1)]</i>
aprepitant 125 mg on Day 1 and 80 mg on Days 2 and 3	intravenous 2 mg prior to 3-day regimen of aprepitant and on Days 4, 8 and 15	2
aprepitant 125 mg on Day 1	intravenous 2 mg given 1 hour after aprepitant	midazolam AUC ↑ 1.5-fold
aprepitant 40 mg	oral 2 mg	midazolam AUC ↑ 1.2-fold on Day 1

A difference of less than 2-fold increase of midazolam AUC is not considered clinically important.

Corticosteroids

Dexamethasone: Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 through 5, coadministered with 20 mg dexamethasone on Day 1 and 8 mg dexamethasone on Days 2 through 5, increased the AUC of dexamethasone by 2.2-fold on Days 1 and 5 *[see Dosage and Administration (2.1)]*. A single dose of aprepitant (40 mg) when coadministered with a single dose of dexamethasone 20 mg, increased the AUC of dexamethasone by 1.45-fold, which is not considered clinically significant.

Methylprednisolone: Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, coadministered with 125 mg methylprednisolone IV on Day 1 and 40 mg methylprednisolone orally on Days 2 and 3, increased the AUC of methylprednisolone by 1.34-fold on Day 1 and by 2.5-fold on Day 3. Although the concomitant administration of methylprednisolone with the single 40 mg dose of aprepitant has not been studied, a single 40 mg dose of aprepitant produces a weak inhibition of CYP3A4 (based on midazolam interaction study) and it is not expected to alter the plasma concentrations of methylprednisolone to a clinically significant degree.

Chemotherapeutic agents

Docetaxel: In a pharmacokinetic study, aprepitant (125 mg/80 mg/80 mg regimen) did not influence the pharmacokinetics of docetaxel.

Vinorelbine: In a pharmacokinetic study, aprepitant (125 mg/80 mg/80 mg regimen) did

not influence the pharmacokinetics of vinorelbine to a clinically significant degree.

CYP2C9 substrates (Warfarin, Tolbutamide)

Warfarin: A single 125 mg dose of aprepitant was administered on Day 1 and 80 mg/day on Days 2 and 3 to healthy subjects who were stabilized on chronic warfarin therapy. Although there was no effect of aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-) warfarin trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with aprepitant [*see Drug Interactions(7.1)*].

Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was administered prior to the administration of the 3-day regimen of aprepitant and on Days 4, 8, and 15. This effect was not considered clinically important.

Aprepitant, when given as a 40 mg single dose on Day 1, decreased the AUC of tolbutamide by 8% on Day 2, 16% on Day 4, 15% on Day 8, and 10% on Day 15, when a single dose of tolbutamide 500 mg was administered prior to the administration of aprepitant 40 mg and on Days 2, 4, 8, and 15. This effect was not considered significant.

Other Drugs

Oral contraceptives: When aprepitant was administered as a 3-day regimen (125 mg/80 mg/80 mg) with ondansetron and dexamethasone, and coadministered with an oral contraceptive containing ethinyl estradiol and norethindrone, the trough concentrations of both ethinyl estradiol and norethindrone were reduced by as much as 64% for 3 weeks post-treatment.

When a daily dosage of an oral contraceptive containing ethinyl estradiol and norgestimate was administered on Days 1 through 21, and aprepitant 40 mg was given on Day 8, the AUC of ethinyl estradiol decreased by 4% and by 29% on Day 8 and Day 12, respectively, while the AUC of norelgestromin increased by 18% on Day 8 and decreased by 10% on Day 12. In addition, the trough concentrations of ethinyl estradiol and norelgestromin on Days 8 through 21 were generally lower following coadministration of the oral contraceptive with aprepitant 40 mg on Day 8 compared to the trough levels following administration of the oral contraceptive alone [see Drug Interactions(7.1)].

P-glycoprotein substrates: Aprepitant is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of aprepitant with digoxin in a clinical drug interaction study.

5-HT₃ antagonists: In clinical drug interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of ondansetron, granisetron, or hydrodolasetron (the active metabolite of dolasetron).

Effect of Other Drugs on the Pharmacokinetics of Aprepitant

Ketoconazole: When a single 125 mg dose of aprepitant was administered on Day 5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant

increased approximately 3-fold [see Drug Interactions (7.2)].

Rifampin: When a single 375 mg dose of aprepitant (3 times the maximum aprepitant recommended dose) was administered on Day 9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold [see Drug Interactions (7.2)].

Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation (approximately 1.8 times the aprepitant recommended dose), with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC. These pharmacokinetic effects did not result in clinically meaningful changes in ECG, heart rate or blood pressure beyond those changes induced by diltiazem alone [see Drug Interactions (7.2)].

Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation (approximately 0.7 and 1.4 times the maximum aprepitant recommended dose), with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and C_{max} by approximately 20% of both aprepitant and paroxetine. This effect was not considered clinically important.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

Carcinogenicity studies were conducted in Sprague-Dawley rats and in CD-1 mice for 2 years. In the rat carcinogenicity studies, animals were treated with oral doses ranging from 0.05 to 1000 mg/kg twice daily. The highest dose produced a systemic exposure to aprepitant (AUC) of 0.7 to 1.6 times the adult human exposure at the 125 mg/80 mg/80 mg aprepitant regimen. Treatment with aprepitant at doses of 5 to 1000 mg/kg twice daily caused an increase in the incidences of thyroid follicular cell adenomas and carcinomas in male rats. In female rats, it produced hepatocellular adenomas at 5 to 1000 mg/kg twice daily and hepatocellular carcinomas and thyroid follicular cell adenomas at 125 to 1000 mg/kg twice daily. In the mouse carcinogenicity studies, the animals were treated with oral doses ranging from 2.5 to 2000 mg/kg/day. The highest dose produced a systemic exposure of about 2.8 to 3.6 times the adult human exposure at the 125 mg/80 mg/80 mg aprepitant regimen. Treatment with aprepitant produced skin fibrosarcomas at 125 and 500 mg/kg/day doses in male mice.

Mutagenesis

Aprepitant was not genotoxic in the Ames test, the human lymphoblastoid cell (TK6) mutagenesis test, the rat hepatocyte DNA strand break test, the Chinese hamster ovary (CHO) cell chromosome aberration test and the mouse micronucleus test.

Impairment of Fertility

Aprepitant did not affect the fertility or general reproductive performance of male or female rats at doses up to the maximum feasible dose of 1000 mg/kg twice daily (providing exposure in male rats lower than the exposure at the recommended adult

human dose and exposure in female rats at about 1.6 times the adult human exposure at the 125 mg/80 mg/80 mg aprepitant regimen).

14 CLINICAL STUDIES

14.1 Prevention of Nausea and Vomiting Associated with HEC in Adults

Oral administration of aprepitant in combination with ondansetron and dexamethasone (aprepitant regimen) has been shown to prevent acute and delayed nausea and vomiting associated with HEC including high-dose cisplatin, and nausea and vomiting associated with MEC.

In Studies 1 and 2, both multicenter, randomized, parallel, double-blind, controlled clinical studies in adults, aprepitant in combination with ondansetron and dexamethasone was compared with standard therapy (ondansetron and dexamethasone alone) in patients receiving a chemotherapy regimen that included cisplatin greater than 50 mg/m² (mean cisplatin dose = 80.2 mg/m²). See **Table 13**.

In these studies, 95% of the patients in the aprepitant group received a concomitant chemotherapeutic agent in addition to protocol-mandated cisplatin. The most common chemotherapeutic agents and the number of aprepitant patients exposed follows: etoposide (106), fluorouracil (100), gemcitabine (89), vinorelbine (82), paclitaxel (52), cyclophosphamide (50), doxorubicin (38), docetaxel (11).

Of the 550 patients who were randomized to receive the aprepitant regimen, 42% were women, 58% men, 59% White, 3% Asian, 5% Black, 12% Hispanic American, and 21% Multi-Racial. The aprepitant-treated patients in these clinical studies ranged from 14 to 84 years of age, with a mean age of 56 years. A total of 170 patients were 65 years or older, with 29 patients being 75 years or older.

	Day 1	Day 2	Day 3	Day 4				
CINV Aprepitant Regimen								
Oral aprepitant [†]	125 mg	80 mg	80 mg	none				
Oral Dexamethasone [‡]	12 mg	8 mg	8 mg	8 mg				
Ondansetron	5-HT ₃ antagonist [§]	none	none	none				
CINV Standard Thera	ру							
Oral Dexamethasone	20 mg	8 mg twice daily	8 mg twice daily	8 mg twice daily				
	5₋µT _{>}							

Table 13: HEC Treatment Regimens - Studies 1 and 2^*

Ondansetron	antagonist [§]	none	none	none
-------------	-------------------------	------	------	------

- * Aprepitant placebo and dexamethasone placebo were used to maintain blinding.
 † Aprepitant was administered 1 hour prior to chemotherapy treatment on Day 1 and in the
 - morning on Days 2 and 3.
- ‡ Dexamethasone was administered 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 through 4. The 12 mg dose of dexamethasone on Day 1 reflects a dosage adjustment to account for a drug interaction with the aprepitant regimen [see Clinical Pharmacology(12.3)].
- § Ondansetron 32 mg intravenous was used in the clinical trials of aprepitant. Although this dose was used in clinical trials, this is no longer the currently recommended dose. Refer to the ondansetron prescribing information for the current recommended dose.

The antiemetic activity of aprepitant was evaluated during the acute phase (0 to 24 hours post-cisplatin treatment), the delayed phase (25 to 120 hours post-cisplatin treatment) and overall (0 to 120 hours post-cisplatin treatment) in Cycle 1. Efficacy was based on evaluation of the following endpoints in which emetic episodes included vomiting, retching, or dry heaves:

Primary endpoint

• complete response (defined as no emetic episodes and no use of rescue therapy as recorded in patient diaries)

Other prespecified endpoints

- complete protection (defined as no emetic episodes, no use of rescue therapy, and a maximum nausea visual analogue scale [VAS] score less than 25 mm on a 0 to 100 mm scale)
- no emesis (defined as no emetic episodes regardless of use of rescue therapy)
- no nausea (maximum VAS less than 5 mm on a 0 to 100 mm scale)
- no significant nausea (maximum VAS less than 25 mm on a 0 to 100 mm scale)

A summary of the key study results from each individual study analysis is shown in **Table 14**. In both studies, a statistically significantly higher proportion of patients receiving the aprepitant regimen in Cycle 1 had a complete response in the overall phase (primary endpoint), compared with patients receiving standard therapy. A statistically significant difference in complete response in favor of the aprepitant regimen was also observed when the acute phase and the delayed phase were analyzed separately.

Table 14: Percent of Patients Receiving HEC Responding by Treatment Groupand Phase - Cycle 1

	Study 1					
ENDPOINTS	Aprepitant Regimen (N=260) [*] %	Standard Therapy (N=261) [*] %	p-Value	Aprepitant Regimen (N=261) [*] %	Therapy	p-Value
PRIMARY ENDPOINT				1	1 1	
Complete Response						
Overall [†]	73	52	< 0.001	63	43	< 0.001
OTHER PRESPECIFIE	D ENDPOINT	S			· · ·	
Complete Response						

· · · ·	i.				1	
Acute phase [‡]	89	78	< 0.001	83	68	< 0.001
Delayed phase [§]	75	56	< 0.001	68	47	< 0.001
Complete Protection	1					
Overall	63	49	0.001	56	41	< 0.001
Acute phase	85	75	NS¶	80	65	< 0.001
Delayed phase	66	52	< 0.001	61	44	< 0.001
No Emesis						
Overall	78	55	< 0.001	66	44	< 0.001
Acute phase	90	79	0.001	84	69	< 0.001
Delayed phase	81	59	< 0.001	72	48	< 0.001
No Nausea						
Overall	48	44	NS#	49	39	NS¶
Delayed phase	51	48	NS [#]	53	40	NS¶
No Significant Nausea						
Overall	73	66	NS [#]	71	64	NS [#]
Delayed phase	75	69	NS [#]	73	65	NS [#]

Visual analogue scale (VAS) score range: 0 mm=no nausea; 100 mm=nausea as bad as it could be.


 N: Number of patients (older than 18 years of age) who received cisplatin, study drug, and had at least one post treatment efficacy evaluation.

- † Overall: 0 to 120 hours post-cisplatin treatment.
- ‡ Acute phase: 0 to 24 hours post-cisplatin treatment.
- § Delayed phase: 25 to 120 hours post-cisplatin treatment.
- ¶ Not statistically significant when adjusted for multiple comparisons.

Not statistically significant.

In both studies, the estimated time to first emesis after initiation of cisplatin treatment was longer with the aprepitant regimen, and the incidence of first emesis was reduced in the aprepitant regimen group compared with standard therapy group as depicted in the Kaplan-Meier curves in **Figure 1**.

Figure 1: Percent of Patients Receiving HEC Who Remain Emesis Free Over Time - Cycle 1



p-Value <0.001 based on a log rank test for Study 1 and Study 2; nominal p-values not adjusted for multiplicity.


Additional Patient-Reported Outcomes

The impact of nausea and vomiting on patients' daily lives was assessed in Cycle 1 of both studies using the Functional Living Index–Emesis (FLIE), a validated nausea- and vomiting-specific patient-reported outcome measure. Minimal or no impact of nausea and vomiting on patients' daily lives is defined as a FLIE total score greater than 108. In each of the 2 studies, a higher proportion of patients receiving the aprepitant regimen reported minimal or no impact of nausea and vomiting on daily life (Study 1: 74% versus 64%; Study 2: 75% versus 64%).

Multiple-Cycle Extension

In the same 2 clinical studies, patients continued into the Multiple-Cycle extension for up to 5 additional cycles of chemotherapy. The proportion of patients with no emesis and no significant nausea by treatment group at each cycle is depicted in **Figure 2**. Antiemetic effectiveness for the patients receiving the aprepitant regimen was maintained throughout repeat cycles for those patients continuing in each of the multiple cycles.

Figure 2: Proportion of Patients Receiving HEC with No Emesis and No Significant Nausea by Treatment Group and Cycle



14.2 Prevention of Nausea and Vomiting Associated with MEC in Adults

Aprepitant was studied in two randomized, double-blind, parallel-group studies (Studies 3 and 4) in adult patients receiving MEC.

In Study 3, in breast cancer patients, aprepitant in combination with ondansetron and dexamethasone was compared with standard therapy (ondansetron and dexamethasone) in patients receiving a MEC regimen that included cyclophosphamide 750 to 1500 mg/m²; or cyclophosphamide 500 to 1500 mg/m² and doxorubicin (less than or equal to 60 mg/m²) or epirubicin (less than or equal to 100 mg/m²). See **Table 15**.

In this study, the most common combinations were cyclophosphamide + doxorubicin (61%); and cyclophosphamide + epirubicin + fluorouracil (22%).

Of the 438 patients who were randomized to receive the aprepitant regimen, 99.5% were women. Of these, approximately 80% were White, 8% Black, 8% Asian, 4% Hispanic, and less than 1% Other. The aprepitant-treated patients in this clinical study ranged from 25 to 78 years of age, with a mean age of 53 years; 70 patients were 65 years or older, with 12 patients being over 74 years.

	Day 1	Day 2	Day 3
CINV Aprepitant Regimen			
Oral Aprepitant [†]	125 mg	80 mg	80 mg
Oral Dexamethasone	12 mg [†]	none	none
Oral Ondansetron	8 mg x 2 doses [‡]	none	none
CINV Standard Therapy			
Oral Dexamethasone	20 mg [†]	none	none
Oral Ondansetron	8 mg x 2 doses [‡]	8 mg twice daily	8 mg twice daily

Table 15: MEC Treatment Regimens - Studies 3 and 4^*

* Aprepitant placebo and dexamethasone placebo were used to maintain blinding.

† Dexamethasone was administered 30 minutes prior to chemotherapy treatment on Day 1. The 12 mg dose of dexamethasone on Day 1 reflects a dosage adjustment to account for a drug interaction with the aprepitant regimen [see Clinical Pharmacology (12.3)].

‡ The first ondansetron dose was administered 30 to 60 minutes prior to chemotherapy treatment on Day 1 and the second dose was administered 8 hours after first ondansetron dose.

The antiemetic activity of aprepitant was evaluated based on the following endpoints in which emetic episodes included vomiting, retching, or dry heaves:

Primary endpoint

 complete response (defined as no emetic episodes and no use of rescue therapy as recorded in patient diaries) in the overall phase (0 to 120 hours postchemotherapy)

Other prespecified endpoints

- no emesis (defined as no emetic episodes regardless of use of rescue therapy)
- no nausea (maximum VAS less than 5 mm on a 0 to 100 mm scale)
- no significant nausea (maximum VAS less than 25 mm on a 0 to 100 mm scale)

- complete protection (defined as no emetic episodes, no use of rescue therapy, and a maximum nausea visual analogue scale [VAS] score less than 25 mm on a 0 to 100 mm scale)
- complete response during the acute and delayed phases

A summary of the key results from Study 3 is shown in **Table 16**. In Study 3, a statistically significantly (p=0.015) higher proportion of patients receiving the aprepitant regimen (51%) in Cycle 1 had a complete response (primary endpoint) during the overall phase compared with patients receiving standard therapy (42%). The difference between treatment groups was primarily driven by the "No Emesis Endpoint", a principal component of this composite primary endpoint. In addition, a higher proportion of patients receiving the aprepitant regimen in Cycle 1 had a complete response during the acute (0 to 24 hours) and delayed (25 to 120 hours) phases compared with patients receiving standard therapy; however, the treatment group differences failed to reach statistical significance, after multiplicity adjustments.

Table 16: Percent of Patients Receiving MEC Responding by TreatmentGroup and Phase - Cycle 1 of Study 3

ENDPOINTS	Aprepitant Regimen (N=433) [*] %	Standard Therapy (N=424) [*] %	p-Value
PRIMARY ENDPOINT [†]			
Complete Response	51	42	0.015
OTHER PRESPECIFIED ENDPOINTS [†]			
No Emesis	76	59	NS [‡]
No Nausea	33	33	NS
No Significant Nausea	61	56	NS
No Rescue Therapy	59	56	NS
Complete Protection	43	37	NS

* N: Number of patients included in the primary analysis of complete response.

+ Overall: 0 to 120 hours post-chemotherapy treatment.

± NS when adjusted for prespecified multiple comparisons rule; unadjusted p-value <0.001.

Additional Patient-Reported Outcomes

In Study 3, in patients receiving MEC, the impact of nausea and vomiting on patients' daily lives was assessed in Cycle 1 using the FLIE. A higher proportion of patients receiving the aprepitant regimen reported minimal or no impact on daily life (64% versus 56%). This difference between treatment groups was primarily driven by the "No Vomiting Domain" of this composite endpoint.

Multiple-Cycle Extension

In Study 3, patients receiving MEC were permitted to continue into the Multiple-Cycle extension of the study for up to 3 additional cycles of chemotherapy. The antiemetic effect for patients receiving the aprepitant regimen was maintained during all cycles.

In Study 4, aprepitant in combination with ondansetron and dexamethasone was compared with a standard therapy (ondansetron and dexamethasone alone) in patients receiving a MEC regimen that included any intravenous dose of oxaliplatin, carboplatin, epirubicin, idarubicin, ifosfamide, irinotecan, daunorubicin, doxorubicin; cyclophosphamide intravenous (less than 1500 mg/m²); or cytarabine intravenous (greater than 1 g/m²). See **Table 15**. Patients receiving the aprepitant regimen were receiving chemotherapy for a variety of tumor types including 50% with breast cancer, 21% with gastrointestinal cancers including colorectal cancer, 13% with lung cancer and 6% with gynecological cancers.

Of the 430 patients who were randomized to receive the aprepitant regimen, 76% were women and 24% were men. The distribution by race was 67% White, 6% Black or African American, 11% Asian, and 12% multiracial. Classified by ethnicity, 36% were Hispanic and 64% were non-Hispanic. The aprepitant-treated patients in this clinical study ranged from 22 to 85 years of age, with a mean age of 57 years; approximately 59% of the patients were 55 years or older with 32 patients being over 74 years.

The antiemetic activity of aprepitant was evaluated based on no vomiting (with or without rescue therapy) in the overall period (0 to 120 hours post-chemotherapy) and complete response (defined as no vomiting and no use of rescue therapy) in the overall period.

A summary of the key results from Study 4 is shown in **Table 17**. In Study 4, a statistically significantly higher proportion of patients receiving the aprepitant regimen (76%) in Cycle 1 had no vomiting during the overall phase compared with patients receiving standard therapy (62%). In addition, a higher proportion of patients receiving the aprepitant regimen (69%) in Cycle 1 had a complete response in the overall phase (0 to 120 hours) compared with patients receiving standard therapy (56%). In the acute phase (0 to 24 hours following initiation of chemotherapy), a higher proportion of patients receiving aprepitant compared to patients receiving standard therapy were observed to have no vomiting (92% and 84%, respectively) and complete response (89% and 80%, respectively). In the delayed phase (25 to 120 hours following initiation of chemotherapy), a higher proportion of patients receiving aprepitant compared to patients receiving aprepi

In a subgroup analysis by tumor type, a numerically higher proportion of patients receiving aprepitant were observed to have no vomiting and complete response compared to patients receiving standard therapy. For sex, the difference in complete response rates between the aprepitant and standard regimen groups was 14% in females (64.5% and 50.3%, respectively) and 4% in males (82.2% and 78.2%, respectively) during the overall phase. A similar difference for sex was observed for the no vomiting endpoint.

Table 17: Percent of Patients Receiving MEC Responding by TreatmentGroup — Cycle 1 of Study 4

ENDPOINTS	Aprepitant Regimen (N=430)* %	Standard Therapy (N=418) [*] %	p-Value
No Vomiting Overall	76	62	<0.0001
Complete Response Overall	69	56	0.0003

* N = Number of patients who received chemotherapy treatment, study drug, and had at least one post-treatment efficacy evaluation.

14.3 Prevention of Nausea and Vomiting Associated with HEC or MEC in Pediatric Patients

In a randomized, double-blind, active comparator-controlled clinical study that included 302 pediatric patients aged 6 months to 17 years receiving HEC or MEC, aprepitant in combination with ondansetron was compared to ondansetron alone (control regimen) for the prevention of CINV (Study 5). Intravenous dexamethasone was permitted as part of the antiemetic regimen in both treatment groups, at the discretion of the physician. A 50% dose reduction of dexamethasone was required for patients in the aprepitant group, reflecting a dosage adjustment to account for a drug interaction [see *Clinical Pharmacology (12.3)*]. No dexamethasone dose reduction was required for patients who received the control regimen.

Eligible patients had documented malignancy at either an original diagnosis or relapse and were scheduled to receive emetogenic chemotherapy or a chemotherapy regimen not previously tolerated due to vomiting along with ondansetron as part of their antiemetic regimen.

Of the 152 pediatric patients randomized to receive the aprepitant regimen, 55% were male, 45% female, 78% White, 7% Asian, 0% Black, 24% Hispanic, and 13% Multi-Racial. The most common primary malignancies in subjects receiving the aprepritant regimen were osteosarcoma (11%), Ewing's sarcoma (11%), neuroblastoma (9%) and rhabdomyosarcoma (8%). Other concomitant chemotherapy agents commonly administered and the number of aprepitant patients exposed were: vincristine sulfate (65), etoposide (59), doxorubicin (48), ifosfamide (45), carboplatin (39), and cisplatin (35).

The treatment regimens in Study 5 for pediatric patients are defined in **Table 18**. Of the pediatric patients, 29% in the aprepitant regimen and 28% in the control regimen used dexamethasone as part of the antiemetic regimen in Cycle 1.

Table 18: HEC and MEC Treatment Regimens* for Pediatric Patients 6Months to 17 Years of AgeStudy 5

	Day 1	Day 2	Day 3
CINV Aprepitant Regimen			
	3 mg/kg body	2 mg/kg body	2 mg/kg body

Pediatric Patients 6 months to less than 12 Years of Age [†]	weight oral suspension	weight oral suspension	weight oral suspension	
Pediatric Patients 12 to 17 Years of Age [†]	125 mg capsule	80 mg capsule	80 mg capsule	
Ondansetron	Per standard of care [‡]	none	none	
CINV Control Regimen [§]				
Ondansetron	Per standard of care [‡]	none	none	

* Intravenous dexamethasone was permitted at the discretion of the physician. A 50% dose reduction of dexamethasone was required for patients in the aprepitant group, reflecting a dosage adjustment to account for a drug interaction [see Clinical Pharmacology (12.3)]. No dexamethasone dose reduction was required for patients in the control regimen.

- + Aprepitant was administered 1 hour prior to chemotherapy treatment on Days 1, 2, and 3. If no chemotherapy was given on Days 2 and 3, aprepitant was administered in the morning.
- ‡ Ondansetron was administered 30 minutes prior to chemotherapy on Day 1.
- § Aprepitant placebo was used to maintain blinding.

The antiemetic activity of aprepitant was evaluated over a 5-day (120 hour) period following the initiation of chemotherapy on Day 1. The primary endpoint in Study 5 was complete response in the delayed phase (25 to 120 hours following chemotherapy) in Cycle 1. Patients had the opportunity to receive open-label aprepitant in subsequent cycles (Optional Cycles 2-6); however, efficacy was not assessed in these optional cycles. Overall efficacy was based on the evaluation of the following endpoints:

Primary endpoint

• complete response (no vomiting, retching and no use of rescue medication) in the delayed phase (25 to 120 hours following initiation of chemotherapy)

Other prespecified endpoints

- complete response in the acute phase (0 to 24 hours following initiation of chemotherapy)
- complete response in the overall phase (up to 120 hours following initiation of chemotherapy)
- no vomiting (defined as no emesis, retching or dry heaves, regardless of use of rescue medication) in the overall phase
- safety and tolerability

A summary of the key study results is shown in **Table 19**.

Table 19: Percent of Patients Who Responded to Treatment by TreatmentGroup and Phase - Cycle 1 of Study 5

	Aprepitant Regimen n/m (%)	Control Regimen n/m (%)
PRIMARY ENDPOINT		J
Complete Response [*] – Delayed phase	77/152 (50.7)†	39/150 (26.0)
OTHER PRESPECIFIED ENDPOINTS		
Complete Response [*] – Acute phase	101/152 (66.4)‡	78/150 (52.0)
Complete Response [*] – Overall phase	61/152 (40.1)†	30/150 (20.0)

n/m = Number of patients with desired response/number of patients included in time point.

Acute Phase: 0 to 24 hours following initiation of chemotherapy.

Delayed Phase: 25 to 120 hours following initiation of chemotherapy.

Overall Phase: 0 to 120 hours following initiation of chemotherapy.

* Complete Response = No vomiting or retching and no use of rescue medication.

+ p<0.01 when compared to Control Regimen

‡ p<0.05 when compared to Control Regimen

14.4 Prevention of PONV in Adults

In two multicenter, randomized, double-blind, active comparator-controlled, parallelgroup clinical studies (Studies 7 and 8), aprepitant was compared with ondansetron for the prevention of postoperative nausea and vomiting in 1,658 patients undergoing open abdominal surgery. These two studies were of similar design; however, they differed in terms of study hypothesis, efficacy analyses and geographic location. Study 7 was a multinational study including the U.S., whereas, Study 8 was conducted entirely in the U.S.

In the two studies, patients were randomized to receive 40 mg aprepitant, 125 mg aprepitant, or 4 mg ondansetron as a single dose. Aprepitant was given orally with 50 mL of water 1 to 3 hours before anesthesia. Ondansetron was given intravenously immediately before induction of anesthesia. A comparison between the aprepitant 125 mg dose did not demonstrate any additional clinical benefit over the 40 mg dose and is not a recommended dosage regimen *[see Dosage and Administration (2.2)].*

Of the 564 patients who received 40 mg aprepitant, 92% were women and 8% were men; of these, 58% were White, 13% Hispanic American, 7% Multi-Racial, 14% Black, 6% Asian, and 2% Other. The age of patients treated with 40 mg aprepitant ranged from 19 to 84 years, with a mean age of 46.1 years. 46 patients were 65 years or older, with 13 patients being 75 years or older.

The antiemetic activity of aprepitant was evaluated during the 0 to 48 hour period following the end of surgery.

Efficacy measures in Study 7 included:

- no emesis (defined as no emetic episodes regardless of use of rescue therapy) in the 0 to 24 hours following the end of surgery (primary)
- complete response (defined as no emetic episodes and no use of rescue therapy) in the 0 to 24 hours following the end of surgery (primary)
- no emesis (defined as no emetic episodes regardless of use of rescue therapy) in the 0 to 48 hours following the end of surgery (secondary)
- time to first use of rescue medication in the 0 to 24 hours following the end of surgery (exploratory)
- time to first emesis in the 0 to 48 hours following the end of surgery (exploratory).

A closed testing procedure was applied to control the type I error for the primary endpoints.

The results of the primary and secondary endpoints for 40 mg aprepitant and 4 mg ondansetron are described in **Table 20**:

Table 20: Response Rates for Select Efficacy Endpoints (Modified-Intentionto-Treat Population) - Study 7

Treatment	n/m (%)	Aprepitant vs Ondansetron		
			Odds ratio*	Analysis
PRIMARY EN	DPOINTS			
No Vomiting (no emetic epi	0 to 24 hours (sodes)	Superiority)		
Aprepitant 40 mg	246/293 (84)	12.6%	2.1	P<0.001 [†]
Ondansetron	200/280 (71.4)			
		inferiority: If LB [‡] erapy, 0 to 24 ho		
Aprepitant 40 mg	187/293 (63.8)	8.8%	1.4	LB=1.02

Ondansetron	154/280 (55)			
	Complete Response (Superiority: If LB >1) (no emesis and no rescue therapy, 0 to 24 hours)			
Aprepitant 40 mg	187/293 (63.8)	8.8%	1.4	LB=1.02§
Ondansetron	154/280 (55)			
Secondary E	Secondary Endpoint			
	No Vomiting 0 to 48 hours (Superiority) (no emetic episodes)			
Aprepitant 40 mg	238/292 (81.5)	15.2%	2.3	P<0.001 [†]
Ondansetron	185/279 (66.3)			

n/m = Number of responders/number of patients in analysis.

 Δ Difference (%): Aprepitant 40 mg minus Ondansetron.


- * Estimated odds ratio for aprepitant versus Ondansetron. A value of >1 favors aprepitant over Ondansetron.
- + P-value of two-sided test < 0.05.

 \pm LB = lower bound of 1-sided 97.5% confidence interval for the odds ratio.

§ Based on the prespecified fixed sequence multiplicity strategy, aprepitant 40 mg was not superior to Ondansetron.

In Study 7, the use of aprepitant did not affect the time to first use of rescue medication when compared to ondansetron. However, compared to the ondansetron group, use of aprepitant delayed the time to first vomiting, as depicted in **Figure 3**.

Figure 3: Percent of Patients Who Remain Emesis Free During the 48 Hours Following End of Surgery - Study 7



Efficacy measures in Study 8 included:

- complete response (defined as no emetic episodes and no use of rescue therapy) in the 0 to 24 hours following the end of surgery (primary)
- no emesis (defined as no emetic episodes regardless of use of rescue therapy) in the 0 to 24 hours following the end of surgery (secondary)
- no use of rescue therapy in the 0 to 24 hours following the end of surgery (secondary)
- no emesis (defined as no emetic episodes regardless of use of rescue therapy) in the 0 to 48 hours following the end of surgery (secondary).

Study 8 failed to satisfy its primary hypothesis that aprepitant is superior to ondansetron in the prevention of PONV as measured by the proportion of patients with complete response in the 24 hours following end of surgery.

The study demonstrated that 40 mg aprepitant had a clinically meaningful effect with respect to the secondary endpoint "no vomiting" during the first 24 hours after surgery and was associated with a 16% improvement over ondansetron for the no vomiting endpoint.

Table 21: Response Rates for Select Efficacy Endpoints (Modified-Intention-to-Treat Population) - Study 8

Treatment	n/m (%)	Aprepitant vs Ondansetron			
			Odds ratio [*]	Analysis	

Complete Respo (no emesis and no	onse o rescue therapy, 0 t	to 24 hours)		
Aprepitant 40 mg	111/248 (44.8)	2.5%	1.1	0.61
Ondansetron	104/246 (42.3)			
Secondary Endp	oints			
No Vomiting (no emetic episode	es, 0 to 24 hours)			
Aprepitant 40 mg	223/248 (89.9)	16.3%	3.2	< 0.001
Ondansetron	181/246 (73.6)			
No Use of Rescu (for established er	ue Medication mesis or nausea, 0 t	o 24 hours)		
Aprepitant 40 mg	112/248 (45.2)	-0.7%	1	0.83
Ondansetron	113/246 (45.9)			
No Vomiting 0 to (no emetic episode	o 48 hours (Superior es, 0 to 48 hours)	ity)	1	1
Aprepitant 40 mg	209/247 (84.6)	17.7%	2.7	< 0.001

n/m = Number of responders/number of patients in analysis. Δ Difference (%): Aprepitant 40 mg minus Ondansetron.

* Estimated odds ratio: Aprepitant 40 mg versus Ondansetron.
† Not statistically significant after pre-specified multiplicity adjustment.

16 HOW SUPPLIED/STORAGE AND HANDLING

Aprepitant capsules, USP 40 mg, are hard gelatin capsules with opaque white cap and opaque white body containing white to off white colored pellets. The cap is imprinted with 'SZ' and the body is imprinted with '525' in black ink.

NDC 0781-2321-06, unit-dose package of 1 NDC 0781-2321-51, unit-dose package of 5

Aprepitant capsules, USP 80 mg, are hard gelatin capsules with opaque white cap and clear transparent body containing white to off white colored pellets. The cap is imprinted with 'SZ' and the body is imprinted with '528' in black ink.

NDC 0781-2322-68, unit-dose package of 6 NDC 0781-2322-46, unit of use bi-fold package of 2

Aprepitant capsules, USP 125 mg, are hard gelatin capsules with opaque light blue cap and opaque white body containing white to off white colored pellets. The cap is imprinted with 'SZ' and the body is imprinted with '529' in black ink.

NDC 0781-2323-68, unit-dose package of 6 NDC 0781-4063-36, unit of use tri-fold pack containing one 125 mg capsule and two 80 mg capsules.

Storage

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Hypersensitivity Reactions

Advise patients that hypersensitivity reactions, including anaphylaxis, have been reported in patients taking aprepitant. Advise patients to stop taking aprepitant and seek immediate medical attention if they experience signs or symptoms of a hypersensitivity reaction, such as hives, rash and itching, skin peeling or sores, or difficulty in breathing or swallowing.

Drug Interactions

Advise patients to discuss all medications they are taking, including other prescription, non-prescription medication or herbal products [see Contraindications (4), Warnings and Precautions (5.1)].

Warfarin: Instruct patients on chronic warfarin therapy to follow instructions from their healthcare provider regarding blood draws to monitor their INR during the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of aprepitant with each chemotherapy cycle, or following administration of a single 40 mg dose of aprepitant for the prevention of postoperative nausea and vomiting [see Warnings and *Precautions (5.2)*].

Hormonal Contraceptives: Advise patients that administration of aprepitant may reduce

the efficacy of hormonal contraceptives. Instruct patients to use effective alternative or back-up methods of contraception (such as condoms and spermicides) during treatment with aprepitant and for 1 month following the last dose of aprepitant [see Warnings and Precautions (5.3), Use in Specific Populations (8.3)].

Finished Drug Product Manufactured by

Lek Pharmaceuticals d.d.,

SI-1526 Ljubljana, Slovenia for

Sandoz Inc., Princeton, NJ 08540

PATIENT INFORMATION

PATIENT INFORMATION Aprepitant Capsules (a-PRE-pi-tant)

Read this Patient Information before you start taking aprepitant and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment.

What are aprepitant capsules?

Aprepitant capsules are a prescription medicine used:

- with other medicines that treat nausea and vomiting in patients 12 years of age and older to prevent nausea and vomiting caused by certain anti-cancer (chemotherapy) medicines
- In adults to prevent nausea and vomiting after surgery

Aprepitant capsules are not used to treat nausea and vomiting that you already have. Aprepitant capsules should not be used continuously for a long time (chronic use).

Who should not take aprepitant capsules? Do not take aprepitant capsules if you:

- are allergic to aprepitant capsules or any of the ingredients in aprepitant capsules. See the end of this leaflet for a complete list of ingredients in aprepitant capsules.
- are taking pimozide (ORAP[®])

What should I tell my healthcare provider before taking aprepitant capsules?

Before you take aprepitant capsules, tell your healthcare provider if you:

- have liver problems
- are pregnant or plan to become pregnant. It is not known if aprepitant capsules can harm your unborn baby.
 - Women who use birth control medicines containing hormones to prevent pregnancy (birth control pills, skin patches, implants, and certain IUDs) should also use a back-up method of birth that does not contain hormones, such as condoms and spermicides, during treatment with aprepitant capsules and for

1 month after your last dose of aprepitant capsules.

 are breastfeeding or plan to breastfeed. It is not known if aprepitant passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take aprepitant capsules.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Aprepitant capsules may affect the way other medicines work, and other medicines may affect how aprepitant capsules work causing serious side effects.

Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

How should I take aprepitant capsules?

- Capsules of aprepitant by mouth for all 3 doses:
- In children 12 years of age and older who can swallow capsules by mouth, aprepitant is prescribed as capsules of aprepitant by mouth for all 3 doses:
- If you are an adult and are having surgery:
- If you take the blood thinner medicine warfarin sodium (COUMADIN[®], JANTOVEN[®]), your healthcare provider may do blood tests after you take aprepitant to check your blood clotting.
- In children 12 years of age and older who can swallow capsules by mouth, aprepitant is prescribed as capsules of aprepitant by mouth for all 3 doses:
- If you are an adult and are having surgery:
- If you take the blood thinner medicine warfarin sodium (COUMADIN[®], JANTOVEN[®]), your healthcare provider may do blood tests after you take aprepitant to check your blood clotting.
- Take aprepitant capsules exactly as prescribed.
- Swallow aprepitant capsules whole.
- If you are receiving chemotherapy, aprepitant capsules may be taken with or without food.
- If you take too many aprepitant capsules, call your healthcare provider, or go to the nearest hospital emergency room.
- If you are receiving cancer chemotherapy, aprepitant capsules are taken as 3 doses over 3 days starting on the day you have chemotherapy, and for the following 2 days.
- In adults who are receiving chemotherapy, there are 2 ways your healthcare provider may prescribe aprepitant capsules for you:

• Capsules of aprepitant by mouth for all 3 doses:

- You should get a package that has three capsules of aprepitant.
- **Day 1 (Day of chemotherapy)**: Take one 125 mg capsule of aprepitant (opaque light blue and opaque white) by mouth 1 hour before you start your chemotherapy treatment.

- **Day 2 and Day 3**: Take one 80 mg capsule of aprepitant (opaque white and clear transparent) by mouth 1 hour before you start your chemotherapy treatment. If no chemotherapy treatment is given on Days 2 and 3, aprepitant capsules should be taken in the morning.
- In children 12 years of age and older who can swallow capsules by mouth, aprepitant is prescribed as capsules of aprepitant by mouth for all 3 doses:
 - You should get a package that has 3 capsules of aprepitant.
 - **Day 1 (Day of chemotherapy)**: Take one 125 mg capsule of aprepitant (opaque light blue and opaque white) by mouth 1 hour before you start our chemotherapy treatment.
 - **Day 2 and Day 3**: Take one 80 mg capsule of aprepitant (opaque white and clear transparent) by mouth 1 hour before you start your chemotherapy treatment. If no chemotherapy treatment is given on Days 2 and 3, aprepitant should be taken in the morning.
- If you are an adult and are having surgery:
- Your doctor will prescribe a 40 mg capsule of aprepitant for you before surgery. Take aprepitant capsule within three hours before surgery.
- Follow your doctor's instructions about restrictions on eating and drinking before surgery.
- If you take the blood thinner medicine warfarin sodium (COUMADIN[®], JANTOVEN[®]), your healthcare provider may do blood tests after you take aprepitant to check your blood clotting.

What are the possible side effects of aprepitant capsules?

- In adults taking aprepitant capsules, the most common side effects include tiredness, diarrhea, weakness, indigestion, stomach (abdominal) pain, hiccups, decrease in white blood cell count, dehydration, changes in liver function tests.
- In adults taking aprepitant capsules to prevent nausea and vomiting after surgery, the most common side effect include constipation, low blood pressure (hypotension).
- In children 6 months to 17 years of age, the most common side effects decrease in white blood cell count, headache, diarrhea, decreased appetite, cough, tiredness, decrease in red blood cell count, dizziness, and hiccups.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of aprepitant capsules. For more information ask your healthcare provider or pharmacist.

Call your healthcare provider for medical advice about side effects. You may report side effects to Sandoz Inc., at 1-800-525-8747 or FDA at 1-800-FDA-1088.

How should I store aprepitant capsules?

• Store at room temperature, between 68° to 77°F (20° to 25°C).

Keep aprepitant capsules and all medicines out of the reach of children.

General information about the safe and effective use of aprepitant capsules

Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflet. Do not use aprepitant capsules for a condition for which it was not prescribed. Do not give aprepitant capsules to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about aprepitant capsules that is written for health professionals. For more information about aprepitant capsules call Sandoz Inc., at 1-800-525-8747.

What are the ingredients in aprepitant capsules?

Active ingredient: aprepitant

Inactive ingredients: hydroxypropyl cellulose, microcrystalline cellulose, sodium lauryl sulfate and sucrose.

The capsule shell for 40 mg and 80 mg contains gelatin and titanium dioxide. The capsule shell for 125 mg contains FD&C Blue #1, gelatin and titanium dioxide. The capsule is printed with edible black pharmaceutical ink. The printing ink contains black iron oxide, propylene glycol and shellac.

Finished Drug Product Manufactured by

Lek Pharmaceuticals d.d.,

SI-1526 Ljubljana, Slovenia for

Sandoz Inc., Princeton, NJ 08540

The brands listed are the registered trademarks of their respective owners and are not trademarks of Sandoz Inc.

This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: December 2020

Package/Label Display Panel

NDC 0781-2321-06

Aprepitant Capsules, USP

40 mg

Rx only

1 Capsule

WARNING: Do not use if blisters are torn, broken or missing.

This unit-dose package is not child-resistant.



PRINCIPAL DISPLAY PANEL

NDC 0781-2321-51

Aprepitant Capsules, USP

40 mg

Rx only

5 Capsules

WARNING: Do not use if blisters are torn, broken or missing.

This unit-dose package is not child-resistant.



Package/Label Display Panel

NDC 0781-2322-68

Aprepitant Capsules, USP

80 mg

Rx only

6 Capsules

WARNING: Do not use if blisters are torn, broken or missing.

This unit-dose package is not child-resistant.



Package/Label Display Panel

NDC 0781-2322-46

Aprepitant Capsules, USP

80 mg


Rx only

2 Capsules

Each capsule contains 80 mg aprepitant

You have already been given a dose of fosaprepitant dimeglumine for injection or an aprepitant capsule to prevent nausea and vomiting before your chemotherapy on Day 1. The two capsules in this package are to be taken on Days 2 and 3.

For Adults and Pediatric Patients 12 years of age and Older.



Package/Label Display Panel

NDC 0781-2323-68 Aprepitant Capsules, USP 125 mg Rx only

6 Capsules

WARNING: Do not use if blisters are torn, broken or missing.


This unit-dose package is not child-resistant.

SANDOZ A Novartis Division



Package/Label Display Panel

NDC 0781-4063-36 Aprepitant Capsule, USP 125 mg and Aprepitant Capsules, USP 80 mg Rx only 3 Capsules One 125 mg capsule contains 125 mg aprepitant Two 80 mg capsules each containing 80 mg aprepitant



APREPITANT aprepitant capsule			
Product Information Product Type	HUMAN PRESCRIPTION DRUG	ltem Code (Source)	NDC:0781-2321
Route of Administration	ORAL	item code (Source)	

	Ingredient Name	Basis of Stre	ngth Strength
APREPITANT (UN	II: 1NF15YR6UY) (APREPITANT - UNII:1NF15YR6UY		40 mg
nactive Ing	redients		
	Ingredient Name		Strength
	CIFIED (UNII: 2G86QN327L)		
	(UNII: U3JF9)	10133)	
SUCROSE (UNII: (. SULFATE (UNII: 368GB5141J)		
	DE (UNII: 15FIX9V2JP)		
	C OXIDE (UNII: XMOM87F357)		
	COL (UNII: 6DC9Q167V3)		
SHELLAC (UNII: 4	6N107B71O)		
Product Cha	racteristics		
Color	WHITE (opaque) , WHITE (opaque)	Score	no score
Shape	CAPSULE (capsule)	Size	14mm
lavor		Imprint Code	SZ;525
Contains			
Packaging			
# Item Code	Package Description	Marketing Start Date	Marketing End Date
NDC:0781-232	¹⁻ 1 in 1 CARTON	12/27/2016	
1	1 in 1 BLISTER PACK; Type 0: Not a Combinati Product	on	
NDC:0781-232	¹⁻ 5 in 1 CARTON	12/27/2016	
2	1 in 1 BLISTER PACK; Type 0: Not a Combinati Product	on	
	Information		
Marketing	Application Number or Monogram	oh Marketing Start Date	Marketing End Date
Marketing Marketing Category	Citation		
Marketing	Citation ANDA090999	12/27/2016	
- Marketing Category		12/27/2016	

APREPITANT			
aprepitant capsule			
Product Information	n		
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0781-2322

Active Ingre	dient/Active I	Moiety				
	Ingred	ient Name	1	Basis of Streng	gth	Strength
APREPITANT (UN	III: 1NF15YR6UY) (A	PREPITANT - UNII:1NF15YR6UY)	AP	REPITANT		80 mg
nactive Ing	redients					
		Ingredient Name				Strength
GELATIN, UNSPE	ECIFIED (UNII: 2G8	6QN327L)				
HYDROXYPROPY	L CELLULOSE (1	200000 WAMW) (UNII: U3JF91U	J133)			
		(UNII: OP1R32D61U)				
	SULFATE (UNII: 3	368GB5141J)				
SUCROSE (UNII:						
	DE (UNII: 15FIX9V2					
	COL (UNII: 6DC9Q	167V3)				
	FOINTO/D/TO/					
	6N107B710)					
	racteristics					
	racteristics WHITE (opaque) , V	WHITE (Clear transparent)		Score		no score
Color Shape	racteristics	· · · · · · · · · · · · · · · · · · ·		Size		18mm
Color Shape Flavor	racteristics WHITE (opaque) , V	· · · · · · · · · · · · · · · · · · ·				
Color Shape Flavor	racteristics WHITE (opaque) , V	· · · · · · · · · · · · · · · · · · ·		Size		18mm
Color Shape Flavor	racteristics WHITE (opaque) , V	· · · · · · · · · · · · · · · · · · ·		Size		18mm
Color Shape Flavor Contains	racteristics WHITE (opaque) , V	· · · · · · · · · · · · · · · · · · ·		Size		18mm
Color Shape Flavor Contains Packaging	Facteristics WHITE (opaque) , V CAPSULE (capsule)	· · · · · · · · · · · · · · · · · · ·		Size Imprint Code		18mm
Color Shape Flavor Contains Packaging # Item Code 1 NDC:0781-232 68	racteristics WHITE (opaque) , V CAPSULE (capsule) Pac 2- 6 in 1 CARTON; Product	kage Description Type 0: Not a Combination		Size Imprint Code ting Start Mate		18mm SZ;528
Color Shape Flavor Contains Packaging # Item Code 1 NDC:0781-232 68	racteristics WHITE (opaque) , V CAPSULE (capsule) Pac 2- 6 in 1 CARTON; Product	kage Description	D	Size Imprint Code ing Start Pate		18mm SZ;528
Color Shape Flavor Contains Packaging # Item Code 1 NDC:0781-232 68 2 NDC:0781-232 46	Pac Pac 2- 6 in 1 CARTON; Product 2- 2 in 1 DOSE PA Product	kage Description Type 0: Not a Combination CK; Type 0: Not a Combination	D 12/27/2016	Size Imprint Code ing Start Pate		18mm SZ;528
Color Shape Flavor Contains Packaging # Item Code 1 NDC:0781-232 68 2 NDC:0781-232 46	Pac 2- 6 in 1 CARTON; Product 2- 2 in 1 DOSE PA	kage Description Type 0: Not a Combination CK; Type 0: Not a Combination	D 12/27/2016	Size Imprint Code ing Start Pate		18mm SZ;528
Color Shape Flavor Contains Packaging # Item Code 1 NDC:0781-232 68 2 NDC:0781-232 46	Pac 2- 6 in 1 CARTON; Product 2- 2 in 1 DOSE PA Product 3 Informati	kage Description Type 0: Not a Combination CK; Type 0: Not a Combination	12/27/2016	Size Imprint Code	I Mark	18mm SZ;528

APREPITANT

aprepitant kit

Product Information

	oduct Type	HUMAN PR	RESCRIPTION DRUG	Iten	n Code (Source)	NDC:07	781-4063
Pa	ckaging							
	Item Code	Markating Start					eting End Date	
	IDC:0781-4063-	1 in 1 DOSE P Product	ACK; Type 0: Not a Cor	nbination	12/27/20			Dute
Qu	antity of Pa	arts						
Part # Package Quantity Total Product Quantity								
Part	1 BLISTER	PACK		2				
Part	t 2 1 BLISTER	PACK		1				
Pa	rt 1 of 2							
AP	PREPITAN	T						
apr	epitant capsu	ule						
Pro	oduct Infor	mation						
Roi	ute of Admini	stration	ORAL					
		Scharlon	0.0.2					
Act	tive Ingredi	ent/Active	Moiety					
Act	tive Ingredi		Moiety dient Name			Basis of S	trength	Strength
	-	Ingre	-	15YR6UY)		Basis of S	trength	Strength 80 mg
	-	Ingre	dient Name	15YR6UY)			trength	-
APR	-	Ing re 1NF15YR6UY)	dient Name	15YR6UY)			trength	-
APR	EPITANT (UNII:	Ing re 1NF15YR6UY)	dient Name				trength	-
APR Ina GEL	EPITANT (UNII: Active Ingre	Ingre 1NF15YR6UY) dients	dient Name (APREPITANT - UNII: 1NF Ingredient Na 586QN327L)	ıme			trength	80 mg
APR Ina GEL HYD	ACTIN, UNSPEC	Ingre 1NF15YR6UY) dients IFIED (UNII: 20 CELLULOSE (dient Name (APREPITANT - UNII: 1NF Ingredient Na 586QN327L) 1200000 WAMW) (UP	ıme			trength	80 mg
APR Ina GEL HYD MIC	ACTIN, UNSPEC PROXYPROPYL ROCRYSTALLI	Ingre 1NF15YR6UY) dients IFIED (UNII: 20 CELLULOSE (NE CELLULOS	dient Name (APREPITANT - UNII: 1NF Ingredient Na 586QN327L) 1200000 WAMW) (UI E (UNII: OP1R32D61U)	ıme			trength	80 mg
APR Ina GEL HYD MIC SOD	ATIN, UNSPEC PROXYPROPYL ROCRYSTALLII	Ingre 1NF15YR6UY) dients IFIED (UNII: 20 CELLULOSE (NE CELLULOS SULFATE (UNII:	dient Name (APREPITANT - UNII: 1NF Ingredient Na 586QN327L) 1200000 WAMW) (UI E (UNII: OP1R32D61U)	ıme			trength	80 mg
APR Ina GEL HYD SOD SUC	ACTIVE INGRE ACTIVE INGRE ATIN, UNSPEC DROXYPROPYL ROCRYSTALLII DIUM LAURYL S CROSE (UNII: C1	Ingre 1NF15YR6UY) dients IFIED (UNII: 20 CELLULOSE (NE CELLULOS SULFATE (UNII: 51H8M554)	dient Name (APREPITANT - UNII: 1NF Ingredient Na 586QN327L) 1200000 WAMW) (UN E (UNII: OP1R32D61U) 5368GB5141J)	ıme			trength	80 mg
APR Ina GEL HYD MIC SOD SUC TITA	ATIN, UNSPEC DROXYPROPYL ROCRYSTALLII DIUM LAURYL S ROSE (UNII: C1 ANIUM DIOXIDI	Ingre 1NF15YR6UY) dients IFIED (UNII: 20 CELLULOSE (NE CELLULOS SULFATE (UNII: 51H8M554) E (UNII: 15FIX9)	dient Name (APREPITANT - UNII: 1NF Ingredient Na 586QN327L) 1200000 WAMW) (UR E (UNII: OP1R32D61U) : 368GB5141J)	ıme			itrength	80 mg
APR Ina GEL HYD MIC SOD SUC TITA FER	ATIN, UNSPEC PROXYPROPYL ROCRYSTALLII DIUM LAURYL S ROSE (UNII: C1 ANIUM DIOXIDI	Ingre 1NF15YR6UY) dients IFIED (UNII: 20 CELLULOSE (NE CELLULOS SULFATE (UNII: 51H8M554) E (UNII: 15FIX9) OXIDE (UNII: XI	dient Name (APREPITANT - UNII: 1NF Ingredient Na 586QN327L) 1200000 WAMW) (UN E (UNII: OP1R32D61U) : 368GB5141J) V2JP) MOM87F357)	ıme			trength	80 mg
APR Ina GEL HYD MIC SOD SUC TITA FER PRO	ATIN, UNSPEC DROXYPROPYL ROCRYSTALLII DIUM LAURYL S ROSE (UNII: C1 ANIUM DIOXIDI	Ingre 1NF15YR6UY) dients IFIED (UNII: 20 CELLULOSE (NE CELLULOS GULFATE (UNII: 51H8M554) E (UNII: 15FIX9N DXIDE (UNII: XI OL (UNII: 6DC9	dient Name (APREPITANT - UNII: 1NF Ingredient Na 586QN327L) 1200000 WAMW) (UN E (UNII: OP1R32D61U) : 368GB5141J) V2JP) MOM87F357)	ıme			trength	80 mg
APR Ina GEL HYD MIC SOD SUC TITA FER PRO	ATIN, UNSPEC DROXYPROPYL ROCRYSTALLI DIUM LAURYL S ROSE (UNII: C1 ANIUM DIOXIDI ROSOFERRIC (DPYLENE GLYC	Ingre 1NF15YR6UY) dients IFIED (UNII: 20 CELLULOSE (NE CELLULOS GULFATE (UNII: 51H8M554) E (UNII: 15FIX9N DXIDE (UNII: XI OL (UNII: 6DC9	dient Name (APREPITANT - UNII: 1NF Ingredient Na 586QN327L) 1200000 WAMW) (UN E (UNII: OP1R32D61U) : 368GB5141J) V2JP) MOM87F357)	ıme			trength	80 mg
APR Ina GEL HYD MIC SOD SUC TITA FER PRO SHE	ATIN, UNSPEC DROXYPROPYL ROCRYSTALLI DIUM LAURYL S ROSE (UNII: C1 ANIUM DIOXIDI ROSOFERRIC (DPYLENE GLYC	Ingre 1NF15YR6UY) dients IFIED (UNII: 20 CELLULOSE (NE CELLULOSE ULFATE (UNII: 51H8M554) E (UNII: 15FIX9) DXIDE (UNII: XI OL (UNII: 6DC9 N107B710)	dient Name (APREPITANT - UNII: 1NF Ingredient Na 586QN327L) 1200000 WAMW) (UN E (UNII: OP1R32D61U) : 368GB5141J) V2JP) MOM87F357)	ıme			trength a a a a a a a a a a a a a a a a a a a	80 mg
APR Ina GEL HYD MIC SOD SUC TITA FER PRO SHE	EPITANT (UNII: ACTIVE INGRE ATIN, UNSPEC DROXYPROPYL ROCRYSTALLII DIUM LAURYL S CROSE (UNII: C1 ANIUM DIOXIDI ROSOFERRIC (DPYLENE GLYC ELLAC (UNII: 461 DOULT Chara	Ingre INF15YR6UY) dients IFIED (UNII: 20 CELLULOSE (NE CELLULOS GULFATE (UNII: 51H8M554) E (UNII: 15FIX9N OXIDE (UNII: XI OL (UNII: 6DC9 N107B710)	dient Name (APREPITANT - UNII: 1NF Ingredient Na 586QN327L) 1200000 WAMW) (UN E (UNII: OP1R32D61U) : 368GB5141J) V2JP) MOM87F357)	I me NII: U3JF91U			itrength itrength i	80 mg

							67.1	
Flavor Imprint Code SZ;528 Contains SZ;528 SZ;528						528		
Con	tains							
Pad	ckaging							
	Item					Marketing Start	Marketing	a End
#	Code		Pacl	cage Description		Date	Date	-
1		2 in 1 l Packag		K; Type 1: Convenien	ce Kit of Co-			
Ma	arketir	ng In	format	ion				
	Marketiı Categoı	ng		tion Number or M Citation	onograph	Marketing Start Date	Marketin Date	-
AND	-	•	ANDA09099	9		12/27/2016		
Pa	rt 2 of	f 2						
	REPIT							
apr	epitant c	apsule	9					
Pro	oduct In	form	ation					
Rou	ite of Ad	minist	ration	ORAL				
Act	ive Ing	redier	nt/Active	Moiety				
			Ingre	dient Name		Basis of Str	ength Sti	rength
APR	EPITANT (UNII: 1N	NF15YR6UY)	APREPITANT - UNII:1N	F15YR6UY)	APREPITANT	125	mg
Ina	ctive In	gredi	ents					
				Ingredient N	ame		Stre	ength
		-	JNII: H3R47K3					
			IED (UNII: 20					
				1200000 WAMW) (U	-	33)		
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U) SODIUM LAURYL SULFATE (UNII: 368GB5141J)								
	ROSE (UN			30003141J)				
			UNII: 15FIX9	/2IP)				
			. (UNII: 6DC9					
	LLAC (UNI			,				
Pro	duct Cl	harac	teristics					

Col	or	BLU	E (opaque lig	ht) , WHITE (opaque)		Score		no score	
Sha	ре	CAP	SULE			Size		19mm	
Fla	vor					Imprint Code		SZ;529	
Cor	ntains								
Pa	ckaging								
#	ltem Code		Pack	age Description	Mai	keting Start Date	Marl	ceting End Date	
1		1 in 1 E Packag		C; Type 1: Convenience Kit of Co-					
Ma	arketii	ng In	format	ion					
	Marketi Catego		Applicat	ion Number or Monograph Citation	Ma	rketing Start Date	Mar	keting End Date	
AND	A		ANDA090999)	12/27	7/2016			
Ma	arketii	ng In	formati	ion					
	Marketi Catego		Applicat	ion Number or Monograph Citation	Ma	rketing Start Date	Mar	Marketing End Date	
AND	A	-	ANDA090999)	12/27	7/2016			
	REPIT epitant ca								
Pre	oduct Ir	form	ation						
Pro	duct Typ	е		HUMAN PRESCRIPTION DRUG	ltem	Code (Source)	ND	C:0781-2323	
Ro	ute of Ad	minist	ration	ORAL					
Act	tive Ing	redier	nt/Active	Moiety					
			Ingred	lient Name		Basis of Stre	ength	Strength	
APR	EPITANT	UNII: 1N	IF15YR6UY) (/	APREPITANT - UNII:1NF15YR6UY)		APREPITANT		125 mg	
Inc	ictive Ir	aradi	onte						
1110		greui	ents	Ingradiant Nama				Strongth	
EDS		IO 1 ///	NII: H3R47K3					Strength	
			ED (UNII: 2G						
				.200000 WAMW) (UNII: U3JF91U	133)				
				(UNII: OP1R32D61U)					

SODIUM LAURYL SULFATE (UNII: 368GB5141J)

SUCROSE (UNII: C151H8M554)

TITANIUM DIOXIDE (UNII: 15FIX9V2JP)

FE	RROSOFERRIC	OXIDE (UNII: XM0M87F357)					
PR	PROPYLENE GLYCOL (UNII: 6DC9Q167V3)						
SH	HELLAC (UNII: 46	N107B71O)					
Pı	roduct Char	acteristics					
Co	olor	BLUE (opaque light) , WHITE (opaque)	Score	no score			
Sł	nape	CAPSULE	Size	19mm			
Fla	avor		Imprint Code	sZ;529			
Co	ontains						
Pa	ackaging						
#	ltem Code	Package Description	Marketing Start Date	Marketing End Date			
1	NDC:0781-2323- 68	1 in 1 CARTON	12/27/2016				
1	NDC:0781-2323- 06	6 in 1 BLISTER PACK; Type 0: Not a Combination Product					
Marketing Information							
Μ	larketing						
M	Marketing Category	Application Number or Monograph Citation	Marketing Star Date	t Marketing End Date			
	Marketing	Application Number or Monograph					

Labeler - Sandoz Inc (005387188)

Revised: 12/2020

Sandoz Inc